University of Naples Federico II

Why Einstein must be wrong: In search of the theory of gravity

Retrieved on: 
Monday, September 25, 2023

Einstein’s theory of gravity — general relativity — has been very successful for more than a century.

Key Points: 
  • Einstein’s theory of gravity — general relativity — has been very successful for more than a century.
  • This is not surprising: the theory predicts its own failure at spacetime singularities inside black holes — and the Big Bang itself.

Deviations and quantum mechanics

    • These signal that Einstein’s theory is failing there and must be replaced with a more fundamental one.
    • Naively, spacetime singularities should be resolved by quantum mechanics, which apply at very small scales.
    • This is enough to understand that a theory that embraces both general relativity and quantum physics should be free of such pathologies.
    • However, all attempts to blend general relativity and quantum physics necessarily introduce deviations from Einstein’s theory.

Cosmology matters

    • A century of research has given us the standard model of cosmology known as the Λ-Cold Dark Matter (ΛCDM) model.
    • Here, Λ stands for either Einstein’s famous cosmological constant or a mysterious dark energy with similar properties.
    • Dark energy was introduced ad hoc by astronomers to explain the acceleration of the cosmic expansion.
    • Despite fitting cosmological data extremely well until recently, the ΛCDM model is spectacularly incomplete and unsatisfactory from the theoretical point of view.

Alternatives to Einstein’s theory

    • That we are observing the first deviations from general relativity while the mysterious dark energy simply does not exist?
    • This idea, first proposed by researchers at the University of Naples, has gained tremendous popularity while the contending dark energy camp remains vigorous.
    • A very popular class of alternatives is the so-called scalar-tensor gravity.

The current situation

    • Theorists have spent the last decade extracting physical consequences from these theories.
    • The recent detections of gravitational waves have provided a way to constrain the physical class of modifications of Einstein gravity allowed.

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Retrieved on: 
Thursday, August 31, 2023

In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.

Key Points: 
  • In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.
  • The FDA requested two Phase III studies and also encouraged the Company to enroll adolescent patients due to Piclidenoson’s strong safety profile demonstrated over its development history and prior clinical studies.
  • The decrease in cash during the six months ended June 30, 2023 is due to the ongoing operations of the Company.
  • The Company's consolidated financial results for the six months ended June 30, 2023 are presented in accordance with US GAAP Reporting Standards.

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

Retrieved on: 
Thursday, August 24, 2023

Can-Fite and Fondazione Telethon have signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment of Lowe Syndrome, a high medical need with no drug available.

Key Points: 
  • Can-Fite and Fondazione Telethon have signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment of Lowe Syndrome, a high medical need with no drug available.
  • Fondazione Telethon is an Italian nonprofit organization whose mission is to advance biomedical research toward the diagnosis, cure, and prevention of genetic diseases, and it established TIGEM in 1994.
  • The Company is not aware of any drug candidates currently in development for the systemic treatment of Lowe Syndrome.
  • Piclidenoson for the treatment of Lowe Syndrome may also qualify for the FDA’s Rare Pediatric Disease Priority Review Voucher, granting an accelerated review process for marketing approval.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Novel biologic Ab-IPL-IL-17™ shows promise for rheumatoid arthritis and inflammatory bowel disease

Retrieved on: 
Tuesday, August 15, 2023

The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Key Points: 
  • The antibody, called Ab-IPL-IL-17™, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.
  • A patent application has been filed covering the antibody and its therapeutic use.
  • The researchers are seeking commercial partners willing to conduct a large-scale clinical evaluation of Ab-IPL-IL17™ in patients with immune-mediated inflammatory diseases (IMIDs).
  • For commercial enquiries contact Dr Veemal Bhowruth at University of Birmingham Enterprise.

Celebrating a Dozen Years of Nurturing Growth: Alimentazione Bambini by Coop Marks its 12th Anniversary

Retrieved on: 
Tuesday, June 20, 2023

Bologna, Italy, June 20, 2023 (GLOBE NEWSWIRE) -- As we celebrate the 12th anniversary of Alimentazione Bambini by Coop, we reflect on a journey filled with dedication, innovation, and a steadfast commitment to nurturing children’s growth.

Key Points: 
  • Bologna, Italy, June 20, 2023 (GLOBE NEWSWIRE) -- As we celebrate the 12th anniversary of Alimentazione Bambini by Coop, we reflect on a journey filled with dedication, innovation, and a steadfast commitment to nurturing children’s growth.
  • This service allows parents to seek advice from our expert medical team, making Alimentazione Bambini by Coop a trusted reference point for parents seeking guidance on child nutrition and health.
  • We’ve also been proud to provide hundreds of healthy and tasty recipes tailored to the nutritional needs of children.
  • This 12th anniversary is a testament to Alimentazione Bambini by Coop’s unwavering commitment to providing high-quality service.

Six Robotics Pioneers Win 2022 Engelberger Awards

Retrieved on: 
Monday, April 25, 2022

The Association for Advancing Automation (A3) today announced six winners of the 2022 Engelberger Robotics Awards, the world's most prestigious robotics honor.

Key Points: 
  • The Association for Advancing Automation (A3) today announced six winners of the 2022 Engelberger Robotics Awards, the world's most prestigious robotics honor.
  • Three more winners will also be celebrated at Automatica in Munich on June 20:
    The Engelberger Robotics Award is named after the late Joseph F. Engelberger, known throughout the world as the founding force behind industrial robotics.
  • Since its inception in 1977, the Engelberger Robotics Award has been presented to 134 robotics leaders from 17 different nations for excellence in technology development, application, education and leadership.
  • As the robotics industry grows, so does our list of extremely talented nominees deserving of this coveted Engelberger Award, said Jeff Burnstein, president of A3.

Global Leaders to Present Breakthroughs in Liquid Biopsy, Early Cancer Detection at S.E.E. Summit

Retrieved on: 
Tuesday, April 19, 2022

Summit plan to extend the program into a series of educational media initiatives to educate and inform cancer patients, healthcare professionals, and the general public.

Key Points: 
  • Summit plan to extend the program into a series of educational media initiatives to educate and inform cancer patients, healthcare professionals, and the general public.
  • Liquid biopsy is a major step forward in cancer detection among all age groups, but it is especially significant for our work at TCA, said Davies.
  • Late detection and misdiagnosis are not uncommon for teens and young adults with cancer, so were thrilled to help bring this good news to mainstream audiences for the first time.
  • Teens and young adults with cancer are long overdue for an upgrade and TCA can hopefully light the fire in Americas health systems.

AAGL to Offer an Extensive Lineup of Postgraduate and Continuing Medical Education Courses for the 50th Annual Global Congress on Minimally Invasive Gynecologic Surgery

Retrieved on: 
Friday, October 15, 2021

The Scientific Program at AAGL annual meetings are always meticulously developed and are renowned for offering the best in MIGS education.

Key Points: 
  • The Scientific Program at AAGL annual meetings are always meticulously developed and are renowned for offering the best in MIGS education.
  • This year's curriculum will consist of PG Courses, Hands-on Surgical Labs, Plenary Sessions, Panels, Debates and Open Communication breakout sessions.
  • Premiering this year, AAGL is excited to introduce AAGL Talks, 15-minute TED-like presentations prior to the General Sessions, that will also provide CME credits.
  • AAGL is a professional medical association of laparoscopic surgeons and is the global leader in minimally invasive gynecologic surgery.